Bone Biologics

Bone Biologics EBITDA per Employee

The EBITDA per Employee of Bone Biologics (BBLG) as of Oct 27, 2026 is -1.62 M USD. In the previous year, EBITDA per Employee was -2.11 M USD — a change of -23.32% (higher).

EBITDA per Employee

-1.62 MUSD

YoY

-23.32%

Last updated:

EBITDA per Employee of Bone Biologics is 2025 -1.62 M USD. EBITDA per Employee of Bone Biologics was 2024 -2.11 M USD. It decreases by -23.32% higher compared to the previous year.

The Bone Biologics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-1.40 M USD
Jan 1, 2019
-1.22 M USD
Jan 1, 2020
-412,507.00 USD
Jan 1, 2021
-550,738.00 USD
Jan 1, 2022
-1.83 M USD
Jan 1, 2023
-4.71 M USD
Jan 1, 2024
-2.11 M USD
Jan 1, 2025
-1.62 M USD
The Bone Biologics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.62 MUSD-23.32%
-2.11 MUSD-55.25%
-4.71 MUSD+157.23%
-1.83 MUSD+232.75%
-550,738.00USD+33.51%
-412,507.00USD-66.29%
-1.22 MUSD-12.31%
-1.40 MUSD+6.26%
-1.31 MUSD-85.29%
-8.93 MUSD+48.83%
-6.00 MUSD+298.41%
-1.51 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bone Biologics Stock analysis

What does Bone Biologics do? Bone Biologics Corp. generates revenue through the development and sale of its NELL-1/DBM Fusion Device, a bone regeneration product for spinal fusion procedures. The device combines NELL-1, a recombinant human protein, with demineralized bone matrix (DBM) to provide targeted bone regeneration control. Medical professionals use the product for spine implants, non-union trauma cases, and osteoporosis treatments. The company's platform technology, centered on NELL-1, is developed through laboratory and animal research to support applications in bone void filling and skeletal regeneration. The firm focuses on osteopromotive applications using NELL-1, a skeletal-specific growth factor proven in laboratory models to replicate human growth and development. NELL-1 is marketed as a bone void filler and is integrated into spinal fusion devices. The company's revenue streams derive from the commercialization of NELL-1-based products targeting orthopedic and spinal surgery markets. Medical device companies and healthcare providers purchase the NELL-1/DBM Fusion Device for clinical use in bone regeneration procedures. Bone Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bone Biologics stock

EBITDA per Employee of Bone Biologics is -1.62 M USD in 2025.

EBITDA per Employee of Bone Biologics changed from -2.11 M USD to -1.62 M USD, representing a -23.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Bone Biologics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Bone Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Bone Biologics

All Key Metrics — Bone Biologics